• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Diomics, Bonne Santé Group enter strategic alliance

March 29, 2021 By Sean Whooley

Diomics Bonne SanteDiomics and Bonne Santé Group announced today that they entered into a strategic alliance to develop a line of Diocare products.

San Diego-based Diomics and Miami-based Bonne Santé Group, which operated through its Bonne Santé Natural Manufacturing division, entered the agreement in an effor tto develop, launch and distribute the Diocare products formulated to address the COVID-19 pandemic, according to a news release.

Diomics’ product line includes Diocare nasal biome defense spray, Diocare dual IgG/IgA respiratory immunity capsules, Diocare week1 interferon support drink mix, Diocare cough relief and immune health syrup, Diocare cough relief and immune health soft chews and the Diocare anti-fatigue and neuroprotective symptom relief capsules.

“The Diocare product line is our best of nature response to supporting people around the world as they seek protective, symptom support and recovery strategies as we all make our way through this pandemic together,” Diomics CMO Bill Shepard said in the release.

“We are extraordinarily pleased that Diomics chose Bonne Santé to be its partner in the development and rollout of Diocare™,” added Bonne Santé CEO Ryan Zackon. “There could not be a more important and relevant product brought to market given the world we are now living in. Bonne Santé Natural Manufacturing prides itself on the provision of our world-class services ranging from formulation and manufacturing to supply chain as a service as we bring Diocare to market.”

Filed Under: Business/Financial News, Contract Services, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: Bonne Sante Group, coronavirus, COVID-19, Diomics

IN CASE YOU MISSED IT

  • Lyra Therapeutics appoints new chief medical officer
  • FDA lifts hold on Vertex’s insulin-producing cell therapy for diabetes
  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS